Výsledky vyhledávání - "DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Hodgkin Disease"

Whole-body MRI versus an [18F]FDG-PET/CT-based reference standard for early response assessment and restaging of paediatric Hodgkin’s lymphoma: a prospective multicentre study: a prospective multicentre study

Autoři: Suzanne Spijkers Annemieke S. Littooij Thomas C. Kwee a další

Přispěvatelé: Suzanne Spijkers Annemieke S. Littooij Thomas C. Kwee a další

Zdroj: Eur Radiol
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname

Témata: Hodgkin disease, Adolescent, Diffusion magnetic resonance imaging, PET/CT, Positron emission tomography computed tomography, observer variation, THERAPY, DISEASE, 03 medical and health sciences, 0302 clinical medicine, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Journal Article, Humans, Whole Body Imaging, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Hodgkin Disease, Prospective Studies, MASSES, Hodgkin, Malaltia de - Imatgeria, Child, Neoplasm Staging, Whole-body imaging, Pediatria, Positron emission tomography computed tomography, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::enfermedad de Hodgkin, Otros calificadores::Otros calificadores::Otros calificadores::/diagnóstico por imagen, Other subheadings::Other subheadings::Other subheadings::/diagnostic imaging, EMC MM-02-54-03, Reference Standards, Hodgkin Disease, Magnetic Resonance Imaging, observer variation, 3. Good health, Multicenter Study, Diffusion Magnetic Resonance Imaging, Radiology Nuclear Medicine and imaging, Paediatric, Imatgeria per ressonància magnètica, Radiopharmaceuticals

Popis souboru: application/pdf

Přístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00330-021-08026-1.pdf
https://pubmed.ncbi.nlm.nih.gov/34021390
https://hdl.handle.net/11351/7784
https://pure.eur.nl/en/publications/89f34ffe-a48f-4898-8bec-f1d19be6186d
https://doi.org/10.1007/s00330-021-08026-1
https://hdl.handle.net/11370/48702bb2-b42d-45c3-a534-5493f110996b
https://research.rug.nl/en/publications/48702bb2-b42d-45c3-a534-5493f110996b
https://doi.org/10.1007/s00330-021-08026-1
https://link.springer.com/content/pdf/10.1007/s00330-021-08026-1.pdf
https://khepri-node.dev.meta-infra.org/papers/whole-body-mri-versus-an-18ffdg-petct-based/34021390
https://europepmc.org/article/MED/34021390
https://www.ncbi.nlm.nih.gov/pubmed/34021390
https://pubmed.ncbi.nlm.nih.gov/34021390/
https://link.springer.com/article/10.1007/s00330-021-08026-1
https://dspace.library.uu.nl/handle/1874/442864

A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma

Autoři: Carlo-Stella, Carmelo ZINZANI, PIER LUIGI Sureda, Anna a další

Přispěvatelé: Carlo-Stella, Carmelo ZINZANI, PIER LUIGI Sureda, Anna a další

Zdroj: Scientia

Témata: Anticossos monoclonals - Ús terapèutic, Hodgkin, Malaltia de - Tractament, Limfomes - Tractament, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Other subheadings::Other subheadings::/therapeutic use, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, T-Cell::Lymphoma, T-Cell, Peripheral, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Hodgkin Disease, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, Otros calificadores::Otros calificadores::/uso terapéutico, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células T::linfoma de células T periféricas, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::enfermedad de Hodgkin

Popis souboru: application/pdf

Relation: Hematological Oncology;41(1); https://doi.org/10.1002/hon.3089; https://hdl.handle.net/11351/9525; 000876789000001

Dostupnost: https://hdl.handle.net/11351/9525
https://doi.org/10.1002/hon.3089

A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma

Autoři: Carlo-Stella C. Zinzani P. L. Sureda A. a další

Přispěvatelé: Carlo-Stella C. Zinzani P. L. Sureda A. a další

Zdroj: Hematol Oncol
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Carlo-Stella, C, Zinzani, P L, Sureda, A, Araújo, L, Casasnovas, O, Carpio, C, Yeh, S-P, Bouabdallah, K, Cartron, G, Kim, W S, Cordoba, R, Koh, Y, Re, A, Alves, D, Chamuleau, M, le Gouill, S, López-Guillermo, A, Moreira, I, van der Poel, M W M, Abbadessa, G, Meng, R, Ji, R, Lépine, L, Saleem, R & Ribrag, V 2022, 'A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma', Hematological Oncology. https://doi.org/10.1002/hon.3089

Témata: 0301 basic medicine, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized, Other subheadings::Other subheadings::/therapeutic use, BONE-MARROW, diffuse large B-cell lymphoma, Otros calificadores::Otros calificadores::/uso terapéutico, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados, Antibodies, Monoclonal, Humanized, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, T-Cell::Lymphoma, T-Cell, Peripheral, B7-H1 Antigen, 03 medical and health sciences, BRENTUXIMAB VEDOTIN, HODGKIN-LYMPHOMA, MULTIPLE-MYELOMA, Hodgkin, Malaltia de - Tractament, Humans, DISEASES::Neoplasms::Neoplasms by Histologic Type::Lymphoma::Hodgkin Disease, peripheral T-cell lymphoma, CELL LYMPHOMA, Non-hodgkin lymphoma, Anticossos monoclonals - Ús terapèutic, non-Hodgkin lymphoma, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::enfermedad de Hodgkin, NIVOLUMAB, ENFERMEDADES::neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células T::linfoma de células T periféricas, Peripheral T-cell lymphoma, Lymphoma, T-Cell, Peripheral, SAR650984, Diffuse large B-cell lymphoma, Original Articles, Cemiplimab, Isatuximab, Hodgkin Disease, 3. Good health, CD38 EXPRESSION, Limfomes - Tractament, cemiplimab, Lymphoma, Large B-Cell, Diffuse, isatuximab

Popis souboru: application/pdf

Přístupová URL adresa: https://pubmed.ncbi.nlm.nih.gov/36251503
https://hdl.handle.net/11351/9525
https://ashpublications.org/blood/article/138/Supplement%201/4362/481644/A-Phase-1-2-Open-Label-Multicenter-Study-of
https://research.vumc.nl/en/publications/aabcdab3-4c50-427d-a57e-a55162101de0
https://hdl.handle.net/11585/904789
https://onlinelibrary.wiley.com/doi/full/10.1002/hon.3089
https://doi.org/10.1002/hon.3089